Foundayo vs. Wegovy Pill: Two Oral GLP-1s, One Decision
For the first time in weight-management history, patients have two FDA-approved GLP-1 pills to choose from. The Wegovy pill (oral semaglutide, launched January 2026) and Foundayo (orforglipron, approved April 2026) both work — but they're built on fundamentally different chemistry.
Head-to-Head Comparison
| Feature | Wegovy Pill | Foundayo |
|---|---|---|
| Active ingredient | Semaglutide (peptide) | Orforglipron (small molecule) |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Frequency | Once daily | Once daily |
| Take with food? | No — empty stomach, 30-min fast | Yes — anytime, with or without food |
| Water restriction? | Max 4 oz water | None |
| Avg. weight loss | ~17% (on-treatment, OASIS 4) | 7.5–11.2% (dose-dependent) |
| Receptor targets | GLP-1 | GLP-1 |
| Self-pay price | $149/mo (starting), $199–$299 higher | $149/mo via LillyDirect |
| FDA approval | December 2025 | April 2026 |
| Refrigeration | No | No |
| Medicare Bridge | Yes (July 2026) | Yes (July 2026) |
The Case for Wegovy Pill
Higher efficacy. In the OASIS 4 trial, patients who stayed on the Wegovy pill lost approximately 17% of their body weight — approaching injectable-level results. For patients whose primary goal is maximum weight loss and who can commit to the fasting protocol, Wegovy pill is the more potent option.
Longer clinical track record. Semaglutide has been studied extensively since 2012 across multiple indications. The safety and efficacy profile is deep. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events.
The Case for Foundayo
Convenience. No fasting. No water restrictions. No timing around meals. You can take Foundayo at lunch, at bedtime, or anywhere in between. For patients with irregular schedules, this is a genuine adherence advantage.
Different chemistry. As a small molecule (not a peptide), orforglipron doesn't require the protective formulation technology that oral semaglutide needs. This could mean more predictable absorption and fewer drug-food interactions.
Lower GI side effects in some patients. While both medications cause nausea, diarrhea, and vomiting in some users, the side-effect profiles differ slightly due to the different molecular mechanisms.
What About Cost?
Both start at $149/mo for self-pay patients at their lowest doses. At higher doses, pricing diverges — Wegovy pill goes up to $299/mo, while Foundayo pricing through LillyDirect varies. Check both before deciding.
If you're not committed to brand-name, compounded semaglutide remains the most affordable GLP-1 option: